{
    "code": "52026656",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52026656",
    "time": "2021-07-23 03:14:16",
    "許可證字號": "衛部藥輸字第026656號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "114\/11\/13",
    "發證日期": "104\/11\/13",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "通關簽審文件編號": "DHA05202665601",
    "中文品名": "億珂膠囊140毫克",
    "英文品名": "Imbruvica Capsules 140mg",
    "適應症": "1. 被套細胞淋巴瘤：適用於先前曾接受至少一種療法治療的被套細胞淋巴瘤Mantle Cell Lymphoma (MCL)成年病人。\r\n2. 慢性淋巴球性白血病\/小淋巴球性淋巴瘤：適用於治療慢性淋巴球性白血病Chronic Lymphocytic Leukemia (CLL)\/小淋巴球性淋巴瘤Small Lymphocytic Lymphoma (SLL)成年病人。 \r\n3. 17p缺失性之慢性淋巴球性白血病\/小淋巴球性淋巴瘤：適用於治療患有17p缺失性之慢性淋巴球性白血病Chronic Lymphocytic Leukemia (CLL)\/小淋巴球性淋巴瘤 (SLL)的成年病人。 \r\n4. Waldenström氏巨球蛋白血症：適用於治療Waldenström氏巨球蛋白血症 (Waldenström’s macroglobulinemia (WM))的成年病人。 \r\n5. 邊緣區淋巴瘤：適用於治療須接受全身性治療且先前曾接受至少一種抗CD20療法的邊緣區淋巴瘤Marginal Zone Lymphoma (MZL)成年病人。 \r\n6. 慢性移植體抗宿主疾病：適用於治療使用一線或多線全身性療法治療失敗後的慢性移植體抗宿主疾病chronic Graft-Versus-Host Disease (cGVHD)成年病人。",
    "劑型": "130膠囊劑",
    "包裝": "8-1000粒塑膠瓶裝(HDPE)",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "06須由醫師處方使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "109\/11\/13",
    "主成分略述": "Ibrutinib",
    "限制項目": "02輸　入 1S須執行確認性療效臨床試驗 51免除銜接性臨床試驗",
    "申請商名稱": "1507401100  嬌生股份有限公司",
    "申請商地址": "台北市中山區民生東路三段2號10樓及11樓",
    "主製造廠": [
        {
            "製造廠名稱": "FUS0774100  CATALENT CTS, LLC",
            "製造廠廠址": "10245 HICKMAN MILLS DRIVE KANSAS CITY, MO 64137, USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "6132061151  裕利股份有限公司",
            "製造廠廠址": "桃園市大園區和平里1鄰開和路91號",
            "製造廠公司地址": "",
            "製造廠國別": "TAIWAN",
            "製程": "二級包裝廠"
        },
        {
            "製造廠名稱": "FUS2401000  AndersonBrecon Inc",
            "製造廠廠址": "4545 ASSEMBLY DRIVE, ROCKFORD, IL 61109 USA",
            "製造廠公司地址": "",
            "製造廠國別": "UNITED STATES",
            "製程": "包裝"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1013005100",
            "成分名稱": "Ibrutinib",
            "含量描述": "",
            "含量": "140.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "",
        "特殊劑型": "",
        "顏色": "",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Imbruvica capsules-108-03-29(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026656&Seq=002&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "3_億珂膠囊140毫克_美國廠仿單v2101 (3p_a_i_4331_v1)_20210524-110-06-03.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026656&Seq=013&Type=9"
        },
        {
            "title": "Imbruvica photo_20201103-109-11-10(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026656&Seq=016&Type=8"
        },
        {
            "title": "產品外觀照片-106-03-20(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026656&Seq=015&Type=8"
        },
        {
            "title": "Imbruvica-shipper label-106-01-05.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52026656&Seq=014&Type=8"
        }
    ]
}